- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02301000
IMT for Primary Clostridium Difficile Infection
Intestinal Microbiota Therapy Versus Metronidazole for Primary Clostridium Difficile Infection: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Up to one third of patients with clostridium difficile infection treated with antibiotics experience recurrent or relapsing symptoms within a few weeks. Even with subsequent antibiotic treatment, multiple recurrences/relapses are frequent. Fecal microbiota transplantation (FMT) has been shown to be significantly more effective in curing recurrent CDI than repeated antibiotic treatment. In current guidelines, FMT is proposed as a treatment option after multiple recurrences/relapses of CDI. The rationale to reserve transplantation of donor feces for recurrent and difficult cases of CDI is a possible risk of pathogen transmittance and the cumbersome and costly process of finding a donor and screen for communicable disease. The effect of FMT for recurrent CDI, however, suggests that this therapy may be more effective than antibiotics in inducing a durable cure also for primary CDI.
We aim to use an anaerobically cultivated human intestinal microbiota (ACHIM) that has been extensively tested for pathogens, from a donor screened for communicable diseases, to avoid the need for a case-by-case donor screening. The term Intestinal Microbiota Therapy (IMT) will be used to describe the ACHIM treatment.
Patients with a first occurrence of CDI defined by diarrhea, as defined by the World Health Organization, and a positive stool test for toxigenic Clostridium difficile will be randomized 1:1 to either a 10-day course of metronidazole 400 mg t.i.d. or a rectal instillation of 60 ml ACHIM suspension.
Patients will be contacted on day 4 by an unblinded study investigator and on days 35 and 70 by a blinded study investigator to evaluate the treatment effect. In addition, the patients will register the frequency of bowel movements on days 1-4, 7, 14 and 21.
In the case of clinical deterioration, appropriate measures will be undertaken according to current guidelines.
A second instillation of ACHIM suspension will be considered on day 4 in the absence of clinical improvement.
The primary endpoint is the rate of primary cure from CDI and no sign of relapse/recurrence within 70 days, or persistent diarrhea that could be explained by other causes with three consecutive negative stool tests for toxigenic Clostridium difficile.
Treatment failure is defined as persistent diarrhea with a positive stool test for toxigenic Clostridium difficile.
Relapsing or recurrent CDI is defined as diarrhea and a positive stool test for toxigenic Clostridium difficile within 70 days of treatment initiation after an initial resolution of diarrhea.
Preliminary sample size is estimated from a hypothesis of a primary cure rate without recurrence within 70 days of 75 % with metronidazole vs. 87.5 % with IMT.
An interim analysis is planned after inclusion of the first 40 patients to guide the final sample size estimation.
Patients will be recruited at six hospitals in South-East Norway.
Before the start of the pilot phase, an independent data safety and monitoring board (DSMB) was established to monitor potential adverse events, and to advise the study team on the results of the pilot phase of the trial with regard to benefits and harms of the treatment, recruitment, and organization.
We recognized a slower than anticipated recruitment during the pilot phase of the trial. The slow recruitment was due to the current clinical practice of rapid initiation of antibiotic therapy by clinicians, before the trial team could ascertain eligible patients for enrolment.
After the inclusion of 20 eligible patients with concluded follow-up in January 2018, the DSMB met with the trial investigators on January 29 (2018), to discuss the results of the pilot phase. In light of the results, the DSMB recommended to start preparations for the main phase of the trial to validate the magnitude of the effects of FMT in primary CDI. Further, due to the nature of the results of the pilot and its potential implications on clinical practice, the DSMB recommended publication of the pilot data. This was also deemed necessary for adequate recruitment of the main trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kristiansand, Norway
- Sørlandet hospital HF
-
Oslo, Norway
- Oslo University Hospital
-
Oslo, Norway
- Diakonhjemmet Hospital
-
Oslo, Norway
- Lovisenberg sykehus
-
Skien, Norway
- Telemark Hospital HF
-
Tønsberg, Norway
- Sykehuset i Vestfold
-
-
Gjettum
-
Sandvika, Gjettum, Norway, 1346
- Vestre Viken HF, Bærum Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diarrhea as defined by the World Health Organization (passage of 3 or more loose or liquid stools (i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7) per day, or more frequently than is normal for the individual, and
- Positive fecal test for toxigenic Clostridium difficile, and
- No evidence of CDI during the previous year.
Exclusion Criteria:
- Known presence of other stool pathogens known to cause diarrhea.
- Pregnancy and nursing.
- Patients with ongoing antibiotic treatment for other infections that cannot be stopped for at least 12 hours.
- Inflammatory bowel disease.
- Patients incapable of providing informed consent.
- Patients with <3 months life expectancy.
- Serious immunodeficiency caused by chemotherapy or other medication.
- Active immunocompromising disease.
- Patients unable to comply with protocol requirements.
- Patients in need of intensive care who are American Society of Anesthesiologists (ASA) Physical Status classification IV and V.
- Known hypersensitivity to Metronidazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intestinal microbiota therapy
The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
|
60 ml of ACHIM suspension will be administered through a rectal tube
Other Names:
|
Active Comparator: Metronidazole
The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
|
Peroral metronidazole 400 mg t.i.d. for ten days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with cure without recurrence
Time Frame: 70 days
|
Absence of diarrhea and no signs of recurrent CDI within 70 days
|
70 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants without diarrhea
Time Frame: 35 days
|
Absence of diarrhea
|
35 days
|
Number of participants in which there was a need to change treatment
Time Frame: 4 days
|
In the case of primary treatment failure, a change of treatment strategy will be considered according to current guidelines.
|
4 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events related to CDI treatment
Time Frame: 1-70 days
|
Patients will be contacted at 4, 35 and 70 days to identify any adverse events related to the treatment.
Patients can contact a study representative at any time in case of suspected adverse events.
|
1-70 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Michael Bretthauer, Ph.d., University of Oslo
- Principal Investigator: Kjetil K Garborg, MD, Ph.d., Oslo University Hospital
Publications and helpful links
General Publications
- Jorup-Ronstrom C, Hakanson A, Sandell S, Edvinsson O, Midtvedt T, Persson AK, Norin E. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol. 2012 May;47(5):548-52. doi: 10.3109/00365521.2012.672587. Epub 2012 Apr 2.
- Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013 Apr;108(4):500-8. doi: 10.1038/ajg.2013.59. Epub 2013 Mar 19.
- van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med. 2013 May 30;368(22):2145. doi: 10.1056/NEJMc1303919. No abstract available.
- Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T. [Clostridium difficile-associated diarrhea treated with homologous feces]. Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1027-30. Norwegian.
- Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010 Dec;42(11-12):857-61. doi: 10.3109/00365548.2010.499541. Epub 2010 Jul 22.
- Midtvedt T, Norin E, Benno P, Dahlgren AL. Response to Surawicz et al. Am J Gastroenterol. 2013 Dec;108(12):1931-2. doi: 10.1038/ajg.2013.280. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMT CDI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of PennsylvaniaTerminatedSevere Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile InfectionUnited States
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; North Carolina...CompletedClostridium DifficileUnited States
-
University Health Network, TorontoTerminatedRecurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile InfectionCanada
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
Hospital Universitario Evangelico de CuritibaNot yet recruitingClostridium Difficile Infections
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
MJM BontenUniversiteit Antwerpen; Universitätsklinikum Köln; Da VolterraCompletedClostridium DifficileGermany, Spain, France, Greece, Netherlands, Romania
Clinical Trials on Intestinal microbiota therapy
-
Zhongshan Hospital Xiamen UniversityUnknown
-
Zhongshan Hospital Xiamen UniversityCompletedInflammatory Bowel Disease(IBD)China
-
University of MinnesotaCompletedPulmonary Arterial HypertensionUnited States
-
Uppsala UniversityKarolinska InstitutetUnknownIrritable Bowel SyndromeSweden
-
Haukeland University HospitalCompletedIrritable Bowel Syndrome | DysbiosisNorway
-
National Medical Research Center for Therapy and...Center for Strategic Planning and Management of Biomedical Health RisksCompleted
-
Oslo University HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownNon-alcoholic Fatty Liver DiseaseChina
-
Henry Ford Health SystemRecruitingStem Cell Transplant ComplicationsUnited States
-
Per HellströmKarolinska Institutet; Region GävleborgCompletedClostridium DifficileSweden